Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Featured Stories


Bluebird Pushes For Zynteglo Pricing Of Five €315K Annual Installments

CEO Nick Leschly talked to Scrip about the European payment strategy for the one-time gene therapy, which will cost €1.575m over five years if treatment is successful.

Pricing Strategies Gene Therapy Launches

AbbVie Ups The Ante For Upadacitinib At EULAR

With data showing the superiority of its JAK inhibitor over Humira, the US firm is looking beyond treating the symptoms of rheumatoid arthritis to achieving remission.

Immune Disorders Clinical Trials Research and Development Strategies

Boost For Chi-Med As Phase III NET Study Stopped Early On PFS Benefit

Chi-Med is setting a course straight for the Chinese FDA after its targeted therapy hit its PFS target ahead of schedule in neuroendocrine tumors.

Clinical Trials Cancer Companies
Advertisement


 Recent Tweets from Scrip


PRECISION MEDICINE RESEARCH: How Advanced Data Analytics Support The Journey From Clinic to Bedside

Precision medicine offers huge promise to patients and health systems. It can also substantially increase the efficiency of drug development by enabling more focused, data-rich clinical trials.

Read more

Embedding Time-Critical Scheduling in Drug Production

Manufacturing is the engine room of the pharmaceutical industry. Ultimately, a medicine has little value if it does not reach patients on schedule, in the required quantity and quality. Download this whitepaper which discusses time-critical scheduling in drug production.

Download Whitepaper
Advertisement

 

Commercial Explore this Topic

Set Alert for Commercial

Sobi Realigns Focus On Late-Stage Hematology & Immunology Assets

Swedish specialty pharma and rare diseases company seeks to sustain recent rapid revenues growth with increased R&D focus and investments in its hematology and immunology franchises.

BioPharmaceutical Immune Disorders Business Strategies

Finance Watch: Tetraphase Reorganization Follows Troubled Antibiotic Commercialization Path

Tetraphase's plan to downsize may put the company on the same path as now-bankrupt Achaogen. Also, Bain raises $900m for its second life science fund, Provention calls off post-ADA offering and Oncologie raises $80m series B.

Financing Business Strategies Infectious Diseases

Trade War Expansion? STAR Board Aims To Keep Lucrative China Biotech IPOs At Home

China has officially unveiled its newest stock market for pre-revenue high-tech companies, already attracting ChipScreen and marking a new rival to similar bourses in the US and Hong Kong. But some are cautioning that local regulators and investors will need to step up if the so-called China Nasdaq is to gain traction.

China Financing

Upsher-Smith Snaps Up Migraine Assets As Dr Reddy’s Hones Focus

Upsher-Smith has acquired US and other territory rights to two specialty product assets of Dr Reddy’s, which appears to be tweaking the commercialization approach of its proprietary products business.

Commercial Deals

Novimmune Sells Gamifant And IO Assets To Sobi

Swiss biotech Novimmune SA creates newco around Gamifant emapalumab and other immuno-oncology assets and then sells it to Sobi for CHF515m ($519.2m).
Commercial ImmunoOncology

Dainippon Partnership Rejig Helps Healios Focus Resources

Big pharma partner takes on prime development responsibility for novel AMD cell therapy as Japanese venture concentrates resources on other in-progress trials.

Regenerative Medicine Japan

Cipla Trims Staff At Indian Plant As It Eyes Costs

The rumor mill has it that Cipla has effected significant staff cuts at its Pithampur facility in India, as it keeps a sharp eye on costs and drives efficiencies at its manufacturing operations. But the company isn’t saying much except that it routinely conducts "performance-based reviews."

India Manufacturing

BlackThorn Raises $76m To Personalize Medicines For Neurobehavioral Disorders

BlackThorn's series B round will fund the use of AI and machine learning via its PathFinder platform and academic collaborations for the development of targeted therapies.

Financing Neurology

Policy & Regulation Explore this Topic

Set Alert for Policy & Regulation

USAID Reviewing India Financing Effort With Troubled DHFL

The US Agency for International Development (USAID) is monitoring its Indian healthcare financing initiative with Dewan Housing Finance Corporation amid simmering concerns over the liquidity position of the mortgage lender.

India Financing Policy

How Can Korea Grab Window Of Opportunity In AI Drug Development?

Participants at a recent policy forum in Seoul stressed the need to secure appropriate technology and expertise, unify government support and draw up a joint cooperation plan between industry and government as key factors in advancing AI-guided new drug development in South Korea.

South Korea Artificial Intelligence

Pfizer’s Vizimpro On Course For India But Competitive Arena Awaits

Pfizer’s Vizimpro has been endorsed by an expert panel in India, paving the way for its potential introduction on the market, where other EGFR inhibitors including AstraZeneca’s Tagrisso have a head start.

India Approvals

Protalix and Chiesi Plan Q1 2020 Filing For Accelerated FDA Approval

The companies plan to use surrogate endpoint data to win approval to challenge Sanofi and Shire for the Fabry disease market.

Approvals Rare Diseases

Research & Development Explore this Topic

Set Alert for Research & Development

Enanta Hopes To Succeed In RSV With N-Protein Inhibition Approach

Enanta's N-protein inhibitor EDP-938 hit a pair of endpoints in a Phase IIa challenge study, but real-world testing may be a higher hurdle. The company believes its therapeutic approach is more effective than fusion protein prophylactic approaches.

Clinical Trials Respiratory Research & Development

In Hindsight, Savara Wishes It Led With Patient-Reported Secondary Endpoint For Molgradex

Orphan lung disease firm tries to sell Phase III setback in aPAP as a “successful failed study” but investors disagree, cutting Savara’s share price by three-quarters. Biotech hopes to talk with regulators after deeper dive into dataset.

Clinical Trials Drug Approval Standards

Weak SOPHIA OS Signal Dampens Enthusiasm For MacroGenics’ Margetuximab

Whether MacroGenics’ margetuximab can produce an overall survival benefit from the SOPHIA study could be key to its commercial fortunes, say analysts. The company remains optimistic.

Clinical Trials ASCO

Novartis MAXIMISEs Cosentyx PsA Position

Up to two thirds of patients with psoriatic arthritis experience inflammatory back pain and the Swiss major has presented data showing that its best-selling drug achieved rapid and significant improvements.

Clinical Trials Companies
UsernamePublicRestriction

Register

Advertisement